medigraphic.com
Colegio de Medicina Interna de México.

2023, Number 5

<< Back Next >>

Med Int Mex 2023; 39 (5)

Effect of the reduced residual renal function on right ventricular function in patients with chronic renal disease treated with peritoneal dialysis

Carmona RHA, Orihuela RÓ, Castillo HMC, Ventura GMJ, Guevara BG, Paniagua SJR

Language: Spanish
References: 21
Page: 743-751
PDF size: 217.69 Kb.


ABSTRACT

Objective: To determine the effect of the decrease in residual renal function on the right ventricular function in patients with end-stage renal disease treated with peritoneal dialysis.
Material and Method: Secondary analysis of a cohort of patients with a diagnosis of chronic renal failure undergoing peritoneal dialysis treatment, performed from January 2014 to January 2016. We performed a basal and a 6-month follow up echocardiogram and compared right ventricular function in each patient before and after presenting a decrease in renal residual function.
Results: There were included 81 patients, 33 (40.7%) were women and 48 (59.3%) were men; the median age was 58 (20-79) years. The study population was divided into 3 groups according to their renal residual function reduction (decrease ‹ 50%, decrease › 50%, anuric). In the group with residual renal function decrease › any case of right ventricular dysfunction, while in the group with residual renal function decrease ‹ 50% and the anuric group there was no significant difference regarding right ventricular function before and after the decrease in residual renal function, p = 0.5 and p = 0.289, respectively.
Conclusions: We didn’t observe decrease in right ventricular function among the 3 groups of patients with distinct grade of decline of residual renal function.


REFERENCES

  1. Amato D, Álvarez-Aguilar C, Castañeda-Limones R, RodríguezE, Ávila-Díaz M, Arreola F, et al. Prevalence of chronickidney disease in an urban Mexican population. KidneyInt 2005; 68 (Suppl 97): S11-S17. doi: 10.1111/j.1523-1755.2005.09702.x.

  2. Lamiere N, Joffe P, Wiedemann M. Healthcare systems- aninternational review: an overview. Nephrol Dial Transplant1999; 14 (Suppl 6): 3-9. doi: 10.1093/ndt/14.suppl_6.3.

  3. Cueto-Manzano AM, Rojas-Campos E. Status of renalreplacement therapy and peritoneal dialysis in Mexico.Perit Dial Int 2007; 27 (2): 142-8.

  4. Caravaca F, Cid MC, Galán J, García MC, Cubero JJ, ArrobasM, et al. Relación entre el aclaramiento de urea yla tasa del catabolismo proteico en pacientes de DPCA:importancia de la función renal residual. Nefrología 1996;16 (3): 201-88.

  5. Maiorca R, Brunori G, Zubani R, Cancarini GC, Manili L,Camerini C, et al. Predictive value of dialysis adequacy and-nutritional indices for mortality and morbidity in CAPD andHD patients. A longitudinal study. Nephrol Dial Transplant1995; 10: 2295-2305.

  6. Chávez-López EL, Alemán-Ortiz OF, Nando-Villicaña CC,Rosas-Munive E. Síndrome cardiorrenal: Nuevas perspectivas.Rev Mex Cardiol 2015; 26 (1): 39-52.

  7. Kingma JG, Simard D, Rouleau JR. Renocardiac syndromes:physiopathology and treatment stratagems. Can J KidneyHealth Dis 2015; 2 (41): 1-10. doi: 10.1186/s40697-015-0075-4.

  8. Foley RN, Parfrey PS, Samak MJ. Clinical epidemiology ofcardiovascular disease in chronic renal disease. Am J KidneyDis 1998; 32(Suppl 3): S112-S119. doi: 10.1053/ajkd.1998.v32.pm9820470.

  9. Luft FC. Cardiovascular risk in patients with end stage renaldisease. Indian J Nephrol 2001; 11; 77-81.

  10. Santos-Martínez LE. Fisiopatología de la falla ventricularderecha en la hipertensión arterial pulmonar. Arch CardMex 2004; 74 (Sup 2): S353-57.

  11. The USRD Dialysis Morbidity and Mortality Study: Wave2. US Renal Data Systems. Am J Kidney Dis 1997; 30(Suppl1): S67-S85.

  12. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A,Moran J, et al. Effects of increased peritoneal clearances onmortality rates in peritoneal dialysis: ADEMEX, a prospective,randomized, controlled trial. J Am Soc Nephrol 2002;

  13. 13: 1307-1320. doi: 10.1681/ASN.V1351307.13. Marrón B, Remón C, Pérez-Fontán M, Quirós P, Ortíz A.Benefits of preserving residual renal function in peritonealdialysis. Kidney Int. 2008; 73: s42-s51. doi:10.1038/sj.ki.5002600.

  14. Shemin D, Bostom AG, Laliberty P, Dworkin LD. Residualrenal function and mortality risk in hemodialysis patients.Am J Kidney Dis 2001; 38: 85-90. doi: 10.1053/ajkd.2001.25198.

  15. Koo HM, Doh FM, Kim CH, Lee MJ, Kim EJ, Han JH, et al.Changes in echocardiographic parameters according to therate of residual renal function decline in incident peritonealdialysis patients. Medicine (Baltimore) 2015; 94 (7): e427.doi: 10.1097/MD.0000000000000427.

  16. Ramasubbu K, Deswal A, Herdejurgen C, Aguilar D, Frost AE.A prospective echocardiographic evaluation of pulmonaryhypertension in chronic hemodialysis patients in the UnitedStates: prevalence and clinical significance. Int J Gen Med2010; 3: 279- 286. doi: 10.2147/IJGM.S12946.

  17. Issa N, Krowka MJ, Griffin MD, Hickson LJ, Stegall MD, CosioFG. Pulmonary hypertension is associated with reduced patientsurvival after kidney transplantation. Transplantation2008; 86: 1384-1388. doi: 10.1097/TP.0b013e318188d640.

  18. Zlotnick DM, Axelrod DA, Chobanian MC, Friedman S,Brown J, Catherwood E, et al. Noninvasive detection ofpulmonary hypertension prior to renal transplantation isa predictor of increased risk for early graft dysfunction.Nephrol Dial Transplant 2010; 25: 3090-3096. doi: 10.1093/ndt/gfq141.

  19. Kumbar L, Fein PA, Rafiq MA, Borawski C, Chattopadhyay J,Avram MM. Pulmonary hypertension in peritoneal dialysispatients. Adv Perit Dial 2007; 23: 127-131.

  20. Agarwal R. Prevalence, determinants and prognosis ofpulmonary hypertension among hemodialysis patients.Nephrol Dial Transplant 2012; 27(10): 3908-14. doi:10.1093/ndt/gfr661.

  21. Bolignano D, Rastelli S, Agarwal R, Fliser D, Massy Z, Ortiz A,et al. Pulmonary Hypertension in CKD. Am J Kidney Dis 2013;61 (4): 612-22. https://doi.org/10.1053/j.ajkd.2012.07.029.




2020     |     www.medigraphic.com